September 9, 2022

Photys Therapeutics Debuts with $75 Million Series A Funding to Advance New Class of Bifunctional Molecules for Precision Phosphorylation to Modulate and Repair Disease-Driving Proteins

August 31, 2022

Umoja’s Unified Approach to Exceeding the Limitations of Cell Therapy

August 25, 2022

AKTIS ONCOLOGY RAISES $84 MILLION TO ADVANCE NOVEL TARGETED ALPHA RADIOPHARMACEUTICALS

August 18, 2022

Orna goes into orbit on $3.65B Merck megadeal, $221M series B round

August 18, 2022

Orna Therapeutics: circular logic

August 16, 2022

BioImpact Capital, an MPM affiliate, Announces a Multi-Billion Dollar Landmark Transaction in Vaccines and Cancer

August 16, 2022

Merck and Orna Therapeutics Collaborate to Advance Orna’s Next Generation of RNA Technology

August 16, 2022

Orna Therapeutics Raises $221 Million Series B Financing to Advance Circular RNA Platform and Accelerate Programs to the Clinic

June 2, 2022

Chris Bardon Interview (GBR Capital)

June 2, 2022

Repare Therapeutics Announces a Worldwide License and Collaboration Agreement with Roche for Camonsertib (RP-3500)

May 12, 2022

Cullinan Oncology and Taiho Pharmaceutical Announce Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417 and Taiho’s Acquisition of Cullinan Pearl

March 8, 2022

AACR and MPM Oncology Charitable Foundation Announce Two Grants to Support Transformative Cancer Research

March 5, 2022

Harpoon Therapeutics Receives FDA Fast Track Designation for HPN217

January 6, 2022

Top Life Sciences Startups to Watch in 2022

January 6, 2022

FDA Grants Breakthrough Therapy Designation for Cullinan Oncology’s CLN-081 in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer

December 16, 2021

Cullinan Oncology Announces Updated Phase 1/2a Data for CLN-081 in NSCLC EGFR Exon 20 Patients

December 7, 2021

MPM Capital Announces the Addition of Detlev Biniszkiewicz, Ph.D. to its Investment Committee

November 17, 2021

Protego Biopharma Raises $51 Million Series A Financing to Advance the Treatment of Protein Misfolding Diseases

October 29, 2021

Entrada Therapeutics Announces Pricing of Upsized Initial Public Offering

October 22, 2021

ReCode Therapeutics Raises Oversubscribed Series B Financing Round of $80 Million

October 19, 2021

Future Returns: MPM Capital’s Second Oncology Impact Fund Goes Beyond Cancer

October 18, 2021

A single patient is producing insulin after treatment with Vertex’s new diabetes cell therapy

October 18, 2021

MPM Advisor Bill Hahn elected to the National Academy of Medicine

October 11, 2021

Listen to Thomas Barnes, Chief Executive Officer of MPM Company ORNA, on Pioneering circular oRNA therapeutics

October 6, 2021

MPM Capital Raises Biotech’s Largest Impact Investment Fund to Help Finance the Fight Against Cancer and Other Diseases

October 1, 2021

The Next RNA Breakthrough? Maybe Bending Strands Into Circles

September 30, 2021

MPM’s Chris Bardon Speaks on CNBC’s Delivering Alpha

September 23, 2021

MPM Strengthens its Team with the Addition of Accomplished Biotech Executive and Drug Discoverer Wendy Young, PhD

September 21, 2021

MPM Expands its Team with the Appointment of RNA Expert and Leading Biotech Executive Pete Smith, PhD

August 30, 2021

From bench to boardroom: 20 of the most influential biopharma R&D executives in drug development

July 8, 2021

Burrage Capital Joins Forces With MPM

June 21, 2021

Umoja Biopharma Closes an Oversubscribed $210 Million Series B Financing to Expand Integrated Immunotherapy Platforms and Advance Programs to the Clinic

June 14, 2021

GSK pays iTeos $625M upfront to join Merck, Roche and the rest in TIGIT immuno-oncology race

June 14, 2021

iTeos Therapeutics and GSK announce development and commercialisation collaboration for EOS-448, an anti-TIGIT monoclonal antibody, enabling novel next-generation immuno-oncology combinations

June 4, 2021

iTeos Therapeutics Announces New Phase 1/2a Data Indicating Antitumor Activity of inupadenant, its Adenosine A2A Receptor Antagonist, at ASCO 2021

May 25, 2021

These are the 2021 CNBC Disruptor 50 companies

May 7, 2021

Chiasma Reports First Quarter Financial Results and Announced Agreement to Merge with Amryt

May 3, 2021

Werewolf Therapeutics Announces Pricing of Upsized Initial Public Offering

April 13, 2021

Pankaj Bhargava was a central figure in the group fashioning Gilead’s oncology strategy. Now he’s jumped to the VC side and the next-gen game at Dana-Farber

April 13, 2021

MPM Capital Adds to Senior Team with the Appointment of Oncology Leader Pankaj Bhargava, MD as Executive Partner

March 31, 2021

Entrada Therapeutics Announces Closing of $116 Million Series B Financing

March 18, 2021

Aktis Oncology Announces $72M Series A Financing To Advance Breakthrough Radiopharmaceuticals To Treat Solid Tumors

March 18, 2021

Are radiopharmaceuticals ready for the mainstream? Novartis, Bristol Myers Squibb bet yes on MPM’s platform take

March 15, 2021

ElevateBio Scales Disruptive Cell and Gene Therapy Business Model with $525 Million Series C Financing

March 11, 2021

Future Returns: How UBS Surpassed a $5 Billion Impact Goal

March 9, 2021

Takeda to Acquire Maverick Therapeutics

February 24, 2021

Orna Therapeutics Launches with over $100M Raised to Develop a New Class of Fully Engineered Circular RNA Therapies

February 24, 2021

The mRNA era is here. MPM believes the future belongs to oRNA- and Big Pharma wants a seat at the table

January 20, 2021

TCR² Therapeutics Announces Pricing of Public Offering of $140.0 Million of Common Stock

January 19, 2021

AACR and MPM Oncology Charitable Foundation Announce Three Grants to Support Transformative Cancer Research

January 8, 2021

Cullinan Management Announces Pricing of Upsized Initial Public Offering (CORRECTION)

January 7, 2021

Werewolf Therapeutics Completes $72 Million Series B Financing

January 5, 2021

MPM Capital Announces the Promotions of Shinichiro Fuse, Ph.D. and Kristen Laguerre to its Investment Committee

December 18, 2020

Cullinan Oncology Completes $131.2 Million Series C Financing

December 13, 2020

TCR² ANNOUNCES RECIST RESPONSE IN OVARIAN CANCER FROM ONGOING PHASE 1/2 TRIAL

December 8, 2020

Harpoon Therapeutics Reports Clinical Progress Across All Four TriTAC® Pipeline Development Programs

November 30, 2020

Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE™

November 19, 2020

Umoja Biopharma Raises $53M in Series A Financing

October 2, 2020

ONCORUS ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING

September 29, 2020

MPM joins the historic SPAC boom as its blank check company files for an IPO

September 18, 2020

Roden, fresh from BMS-Celgene merger, lands VC role at MPM

September 17, 2020

MPM Capital Bolsters Senior Team with Appointment of Matthew Roden as Executive Partner

September 17, 2020

After leading Celgene buyout, Matthew Roden leaves Bristol Myers Squibb for venture capital firm

September 16, 2020

Dyne Therapeutics Announces Pricing of Initial Public Offering

August 11, 2020

DYNE THERAPEUTICS ANNOUNCES $115 MILLION FINANCING TO ADVANCE PIPELINE OF MODERN OLIGONUCLEOTIDE THERAPEUTICS FOR SERIOUS MUSCLE DISEASES

July 30, 2020

AlloVir Announces Pricing of Upsized Initial Public Offering

July 28, 2020

TCR² THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

July 24, 2020

iTeos Therapeutics Announces Pricing of Initial Public Offering

July 21, 2020

Gilead Sciences Secures Exclusive Option to Acquire Tizona Therapeutics for $300 Million

July 16, 2020

Oncorus Announces Clinical Trial Collaboration with Merck

June 27, 2020

Chiasma Announces FDA Approval of MYCAPSSA® (Octreotide) Capsules, the First and Only Oral Somatostatin Analog

June 23, 2020

Repare Therapeutics Announces Pricing of Upsized Initial Public Offering

June 6, 2020

Cullinan Oncology Completes $98.5 Million Series B Financing

June 1, 2020

After Inking Bristol Myers Pact, Repare Therapeutics Sets Sights on IPO

May 28, 2020

Repare Therapeutics Announces Multi-Target Discovery Collaboration with Bristol Myers Squibb

April 1, 2020

iTeos Therapeutics Closes $125 Million Series B2 Financing

March 31, 2020

ElevateBio Closes $170 Million Series B Financing

March 30, 2020

ReCode Therapeutics Raises $80 Million In Oversubscribed Series A Financing

February 26, 2020

MPM Capital Announces $100M Oncology Innovations Fund as Part of Novel Venture Philanthropy Collaboration with Dana-Farber Cancer Institute

February 26, 2020

WSJ.com – MPM Capital Raises $100 Million Fund, Teams Up With Dana-Farber Cancer Institute

February 26, 2020

FierceBiotech – MPM gains first offer on Dana-Farber tech, raises $100M fund

February 26, 2020

Endpoints News – Tying basic science to spinouts, Dana-Farber debuts sister funds totaling $126M with MPM Capital

February 24, 2020

AACR to Receive $2 Million to Support Innovative Research from UBS Oncology Impact Fund Managed by MPM Capital

February 12, 2020

AlloVir Receives the European Medicines Agency PRIME Designation for Viralym-M, an Allogeneic, Off-the-Shelf, Multi-Virus Specific T-Cell Therapy

February 7, 2020

Dyne Therapeutics Expands Leadership Team with Key Hires

February 5, 2020

CODA Biotherapeutics Acquires Attenua and Three Clinical Stage Assets

January 30, 2020

iTeos Therapeutics Awarded €15 Million in Non-Dilutive Funding by the Walloon Region

January 23, 2020

Epizyme Receives FDA Accelerated Approval of TAZVERIK™ (tazemetostat) for the Treatment of Epithelioid Sarcoma

January 6, 2020

BioIntervene Announces $30 Million Series A Financing

December 17, 2019

The AACR-MPM Oncology Charitable Foundation Announces First Grants to Support Transformative Cancer Research

December 17, 2019

Triplet Therapeutics Launches with $59 Million in Financing to Further Its Development of Transformative Treatments for Triplet Repeat Disorders

November 21, 2019

Harpoon Therapeutics and AbbVie Announce Licensing and Option Collaboration to Advance HPN217, Harpoons’ BCMA-Targeting TriTAC®, and Expand Existing Discovery Collaboration

Overall Deal Potential Valued up to $2.4B

November 20, 2019

Werewolf Therapeutics Launches with $56M Series A Financing to Develop Transformative Immuno-Stimulatory Cancer Medicines

November 18, 2019

Novartis and MPM Capital Invest in SiO2 Medical Products Developing a Potentially Disruptive Novel Packaging Technology

November 15, 2019

New Novartis Medicine Adakveo® (crizanlizumab) Approved by FDA to Reduce Frequency of Pain Crises in Individuals Living with Sickle Cell Disease

Therapy developed by MPM portfolio company Selexys, acquired by Novartis in 2016

November 5, 2019

CODA Biotherapeutics Announces Series A Extension, Bringing Total Round to $34M

October 16, 2019

Rhythm Pharmaceuticals, Inc. Announces Pricing of Public Offering

October 8, 2019

MPM’s Todd Foley Comments on Pharma Market in WSJ Pro VC “Pharma Mergers, Strong IPO Market Mute Startup Acquisitions”

October 7, 2019

TriNetX Named Technology Partner for FDA Sentinel System

September 25, 2019

Blade Therapeutics Expands Anti-Fibrotic Pipeline With Acquisition of ATXCo

September 24, 2019

MPM Capital Executive Partner Patrick Baeuerle Wins 2019 Xconomy “X of the Year” Award

September 24, 2019

Amphivena Closes $62 Million Series C Financing to Expand the Clinical Development of AMV564 into Solid Tumors and to Develop its T Cell Engagement Portfolio

September 23, 2019

MPM Capital Portfolio Company Frontier Medicines Honored with a Fierce 15 Award

September 4, 2019

MPM’s Todd Foley Discusses Acquisition of Semma Therapeutics in WSJ Pro VC “Vertex Makes Another Aggressive Purchase With Semma”

September 4, 2019

Repare Therapeutics Announces US$82.5 Million Series B Financing

September 3, 2019

Semma Therapeutics to be Acquired by Vertex for $950M

August 22, 2019

Iconic Therapeutics Signs Ophthalmology Option Agreement with Novartis

August 21, 2019

Oncorus Announces $79.5 Million Series B Financing to Support the Advancement of Oncolytic Virus Therapies to Transform Outcomes for Cancer Patients

July 26, 2019

Chiasma Announces Pricing Of Underwritten Public Offering Of $55.0 Million Of Common Stock

July 26, 2019

MGH and ElevateBio Announce a 10-Year Alliance Agreement to Utilize ElevateBio BaseCamp to Manufacture Innovative Cell and Gene Therapies

June 25, 2019

Frontier Medicines Launches with $67M Series A Financing

Developing novel medicines that drug previously considered “undruggable” targets, starting with cancer

May 22, 2019

Portfolio Company ElevateBio Announces that Allovir Joins its Portfolio of Highly Innovative Cell and Gene Therapy Companies

May 16, 2019

Iconic Therapeutics And Exelixis Enter into Exclusive Option and License Agreement for Novel Antibody-drug Conjugate Program

May 13, 2019

ElevateBio Launches to Create and Operate a Portfolio of Highly Innovative Cell and Gene Therapy Companies

$150M Series A financing co-led by UBS Oncology Impact Fund Managed by MPM Capital

April 26, 2019

Aratana Therapeutics to be Acquired by Elanco Animal Health

April 3, 2019

AACR-MPM Oncology Charitable Foundation Transformative Cancer Research Grants Program Now Inviting Applications

April 3, 2019

Dyne Therapeutics Launches with $50 Million Series A to Develop Targeted Therapies for Muscle Diseases

March 13, 2019

TriNetX Secures $40 Million in Series D Funding

February 22, 2019

MPM’s Patrick A. Baeuerle Awarded the 2019 Lennart Philipson Award for Contributions to Cancer Immunotherapy

February 22, 2019

BioCentury: MPM Keeps Building

Luke Evnin speaks with Chris Lieu at BioCentury (full article - subscription)

February 21, 2019

The Wall Street Journal: Biotech Investor MPM Capital Refuels With $400 Million Venture Fund

Ansbert Gadicke speaks with Brian Gormley at the Wall Street Journal (full article -subscription)

February 21, 2019

Scrip Pharma intelligence: MPM Raises $400M To Build Early-Stage Biotechs

Ansbert Gadicke speaks with Kevin Grogan at Scrip Pharma intelligence (full article -subscription)

February 21, 2019

Endpoints News: MPM Adds $408M for its Next Big Wave of Biotech Startups — and Oncology Still Dominates the Menu

Luke Evnin speaks with John Carroll at Endpoints News

February 21, 2019

MPM Capital Raises $400 Million to Fund Early-Stage Biotech Innovation

February 20, 2019

Harvard Business Review: Impact Investing Could Accelerate the Fight Against

UBS Oncology Impact Fund managed by MPM cited as a “..model other funds could emulate..”

January 3, 2019

Tizona Therapeutics Appoints Scott Clarke as Chief Executive Officer and Provides Update on Regulatory Milestone for its First-in-Class CD39 program in Cancer

January 3, 2019

Tizona Therapeutics and AbbVie Announce Strategic Collaboration to Develop First-in-Class Immunotherapy for Cancer Targeting CD39

December 18, 2018

Entrada Therapeutics Raises $59 Million Series A to Advance Intracellular Biologics Platform

Series A co-led by 5AM Ventures and MPM Capital, along with other top investors

November 29, 2018

TCR2 Therapeutics wins U.S. Private Company of the Year Award at LifeStars Awards™ Life Sciences 2018 Event

November 12, 2018

Harpoon Therapeutics Announces Closing of $70M Series C Financing

September 25, 2018

Verastem Oncology Receives FDA Approval of COPIKTRA™ (duvelisib) Capsules

Treatment for adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after at least two prior therapies

September 13, 2018

MPM Capital Expands its Team of Executive Partners and Entrepreneurs with the Appointments of Biotech Leaders Detlev Biniszkiewicz and Scott Chappel

September 12, 2018

MPM Capital and Versant Ventures Launch CODA Biotherapeutics to Accelerate Development of Chemogenetic Gene Therapy Platform

Industry veteran Michael Narachi joins as President and CEO

September 6, 2018

Twentyeight-Seven Therapeutics Launches with a $65 Million Series A Funding

August 6, 2018

Harpoon Therapeutics Treats First Patient With HPN424 in Phase 1 Clinical Trial of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients

HPN424, First-in-Class TriTAC™ T Cell Redirection Therapy, Targets Prostate-Specific Membrane Antigen (PSMA)

August 1, 2018

Oncorus®, Inc., Names Industry Veteran Ted Ashburn as new President and CEO

– Company co-founder Mitch Finer named new Chairman of the Board –

July 18, 2018

Maverick Therapeutics Advances Technology; Adds Key Management

James R. Vasselli MD to Lead Clinical Development

June 27, 2018

MPM Executive Partner, David Hallal, Appointed Chairman of iTeos Therapeutics

June 26, 2018

Patrick Baeuerle, MPM Executive Partner and Immunotherapy Pioneer, to Present Compelling Data from Harpoon Therapeutics’ Biotherapeutics Platform at the 2018 European Congress on Biotechnology

June 20, 2018

MPM Leads $75 Million Series B Financing of iTeos Therapeutics

May 29, 2018

Chris Bardon Talks to WSJ Pro VC about Late-Stage Combination Therapy Trials

May 22, 2018

MPM Cancer Research Partnership with AACR Featured in Medpage Today

AACR Ventures into New Cancer Research Funding Model—Adapting model pioneered by Cystic Fibrosis Foundation

May 10, 2018

MPM Portfolio Company Semma Therapeutics Appoints Bastiano Sanna, Ph.D. as CEO and President

May 5, 2018

Chris Bardon Comments to Reuters on the OIF and its Philanthropic Impact

Read: “Executive Perspective: An example of innovative impact investing from UBS”

May 2, 2018

Watch Now: Chris Bardon is a Featured Panelist at Paying for Cures – Global Conference 2018 | Milken Institute

April 23, 2018

MPM’s Approach to Investing is Positively Impacting Cancer Research and Care

Learn more in BioWorld article, “Socially Conscious Investing Benefits AACR, UBS’ Optimus”

April 19, 2018

MPM’s Partnership with AACR Highlighted in WSJ Pro VC “Gormley’s Take: Health-Care Investors Doing Good After Doing Well”

April 18, 2018

MPM Capital Portfolio Company Tetherex Pharmaceuticals Completes $50M Series B Financing

April 16, 2018

MPM and AACR Announce Partnership in Cancer Research

April 16, 2018

Watch Now: Press Event Announcing MPM and AACR Partnership in Cancer Research

Panel from AACR, MPM and UBS Discuss First Funding Gift from UBS Oncology Impact Fund managed by MPM

April 16, 2018

MPM and AACR Partnership Featured in Barron’s Article “UBS Oncology Impact Fund Announces $2.5M in Gifts”

April 15, 2018

Watch Now: Chris Bardon Announces MPM and AACR Partnership in Cancer Research at AACR 2018 Opening Ceremony

April 9, 2018

MPM’s Chris Bardon Comments on Lessons Learned from Recent IO Trial Results

Read BioWorld article “Epacadostat/Keytruda Pivotal Trial Flop Sends Shivers Down IDO Pathway”

March 21, 2018

MPM Portfolio Company TCR2 Therapeutics Raises $125 Million in Oversubscribed Series B Financing

February 20, 2018

Cullinan Oncology and MAB Discovery Announce Collaboration to Develop Novel Antibody-Based Therapeutics

January 24, 2018

Astellas Completes Acquisition of Mitobridge, Inc.

January 11, 2018

BioWorld’s Key Highlights from the Women in Bio and Bloomberg Intelligence Panel with Chris Bardon at JPM18

“Women Have Their Say as All-Female Panel Talks Biopharma Investment, Technology Trends”

January 10, 2018

Syndax Pharmaceuticals Announces Clinical Collaboration to Evaluate Entinostat in Combination with anti-PD-L1 Cancer Immunotherapy in Breast Cancer

January 9, 2018

WATCH NOW: Chris Bardon Discusses the Cycle of Innovation and Value of Transformative Therapies on CNBC

January 9, 2018

Rhythm Pharmaceuticals Enters into Partnership with WuXi NextCODE the Emerging Global Standard Platform for Genomic Data

The partnership will help Rhythm identify genetic markers for rare metabolic syndromes and optimize investigational compounds

January 8, 2018

Chris Bardon Shares her Thoughts on Market Trends and Innovative Therapies with BioWorld

“‘Spirit’ of JPM Lives on as Other Meetings Muscle in on Biopharma Playground”

January 3, 2018

TCR2 Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference

December 9, 2017

Chris Bardon Comments on Positive Gene Therapy Data in Forbes article, “Excitement Builds Around Gene Therapy Cures For Hemophilia”

December 1, 2017

MPM portfolio company, Mitobridge, Inc. to be acquired by Astellas Pharmaceuticals in a deal worth up to $450 million

November 30, 2017

Semma Therapeutics Raises $114m for Novel Diabetes Treatment

October 19, 2017

Syndax Expands Pipeline with Exclusive Worldwide License to Allergan’s Portfolio of Menin-MLL Inhibitors

October 19, 2017

TCR2 Therapeutics Appoints Leading Cell Therapy Expert as Chief Medical Officer

October 19, 2017

Blade Therapeutics Announces Selection of a Clinical Development Candidate and Funding of the Second Tranche for its Series B Financing

October 18, 2017

AbbVie and Harpoon Therapeutics Announce Immuno-Oncology Research Collaboration

October 17, 2017

Mitobridge featured in Bloomberg article, “One Scientist’s Marathon Quest for the Exercise Pill”

October 4, 2017

Rhythm Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering

October 3, 2017

Oncorus®, Inc., Names Christophe Quéva, Ph.D., as Chief Scientific Officer

October 3, 2017

The UBS Oncology Impact Fund Co-leads $150 Million Series A Financing of Cullinan Oncology

Cullinan Oncology is an Innovative Development Company with an Accomplished Management Team to Develop Pipeline of Novel Cancer Therapies

September 26, 2017

Repare Therapeutics Named as One of FierceBiotech’s “Fierce 15” Biotech Companies of 2017

September 16, 2017

Inside Perspectives on Gene Editing: An Interview with MPM Capital’s Mitchell Finer

September 15, 2017

TCR2 Therapeutics Named One of the 15 Innovative Immuno-Oncology Biotechs to Watch in 2018 by Immuno-Oncology Frontiers

September 13, 2017

Oncorus’ Viral Cancer Vaccine Highlighted in WSJ: “Scientists See Progress for Cancer Vaccines”

September 5, 2017

Inside Perspectives on Cancer Immunotherapy: An Interview with MPM’s Christiana Bardon

September 1, 2017

Gormley’s Take: Writing War on Cancer’s Next Chapter –– Biotech startups seek to widen benefits of revolutionary cell-therapy treatments

WSJ Pro Venture Capital features MPM’s Chris Bardon and TCR2

August 31, 2017

MPM’s Chris Bardon Applauds Novartis’ Value-Based Pricing Move for its CAR-T Cell Therapy Kymriah

Read BioWorld article “Gene therapy, cloaked in cell therapy, arrives in U.S. courtesy of Kymriah”

August 11, 2017

Maverick Therapeutics Appoints James S. Scibetta as CEO

July 27, 2017

MPM’s Chris Bardon Talks to BioWorld About Recent Pharma R&D Restructuring

Trends point to pharma focus on signing more early stage partnerships

July 17, 2017

Radius Health Appoints Jesper Høiland as President and Chief Executive Officer

Leading the Next Stage Of Growth and Value Creation As A Fully Integrated Commercial Biotech Company

June 28, 2017

Semma Therapeutics Mentioned in WSJ article “Biotech Startups’ Cell-Based Diabetes Attack”

June 22, 2017

MPM and Versant Venture Co-Lead Series A Financing of Repare Therapeutics

June 21, 2017

Proteon Therapeutics Announces $22.0 Million Private Placement

June 20, 2017

Visionary Scientist Stephen J. Elledge Joins MPM Capital’s Medical and Scientific Advisory Board

June 13, 2017

Accomplished Oncologist and Scientist William C. Hahn Joins MPM Capital’s Oncology Impact Fund Advisory Board

June 8, 2017

TCR2 Therapeutics to Debut Positive Solid Tumor Data on its Novel TRuC™ Engineered T Cell Platform at the World Preclinical Congress

June 6, 2017

Radius Presents Positive Data From A Fully Enrolled Ongoing Phase I Study for Investigational Drug Elacestrant (RAD1901) at the 2017 American Society of Clinical Oncology Annual Meeting (ASCO)

May 25, 2017

Amgen vet Patrick Baeuerle inspires a $45M round from A-list VCs for a next-gen I/O drug platform

May 25, 2017

Harpoon Therapeutics Announces Completion of $45M Series B Financing

May 23, 2017

MPM Portfolio Company True North Therapeutics Acquired by Bioverativ, Inc

Upfront payment of $400M plus assumed cash, with additional payments of up to $425M contingent on the achievement of future milestones

May 18, 2017

Syndax Shares Soar as Lead Drug Clears a Mid-Stage Cancer Drug Study Hurdle

May 4, 2017

Conatus Announces Exercise of License Option for Global Development and Commercialization of Emricasan Following Notice of Initiation of Phase 2b ENCORE-LF Clinical Trial in NASH Cirrhosis

May 3, 2017

Inside Perspectives on Cancer Immunotherapy: An Interview with MPM’s Christiana Bardon

April 28, 2017

FDA Approves MPM Portfolio Company Radius Health’s TYMLOS™ (abaloparatide)

Bone Building Agent for the Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture

April 17, 2017

Meet One the Most Successful German Biotech Leaders Ever Read more about MPM’s Patrick Baeuerle

April 5, 2017

MPM Managing Director Chris Bardon Named a Top-40 Transformer

Top innovation gurus leading the biopharma industry's transformation are recognized by MM&M

April 4, 2017

MPM Portfolio Company Oncorus Nominated for 2017 NEVY Award as Hottest Early-Stage Startup Therapeutics

April 4, 2017

Syndax Pharmaceuticals Adds Biopharmaceutical Industry Leader Keith A. Katkin to Board of Directors

February 16, 2017

Rhythm Announces Completion of $41 Million Mezzanine Financing

— Proceeds to finance significant expansion of genetic obesity clinical trials —

February 7, 2017

Chris Varma, Co-founder and Former President and CEO of Blueprint Medicines, Joins MPM as Entrepreneur-in-Residence

January 11, 2017

MPM Portfolio Company Maverick Therapeutics and Takeda Announce Five-year Collaboration to Advance T-Cell Engagement Therapies

January 5, 2017

Accomplished Biotech Investor Ed Hurwitz Joins MPM as Managing Director

December 19, 2016

MPM Portfolio Company, Astute Medical, Forms Strategic Partnership with Bio-Techne

December 19, 2016

Novartis Signs Exclusive Option, Collaboration and License Agreement with MPM Portfolio Company Conatus Pharmaceuticals Inc.

December 15, 2016

Oncorus®, Inc. Announces Additional Series A Financing Support From Astellas Venture Management LLC

December 13, 2016

Harpoon Therapeutics Appoints Gerald McMahon, Ph.D., as President and CEO

December 8, 2016

TCR2 Therapeutics Launches from Stealth Mode to Accelerate Development of Novel Cancer Immunotherapies

- $44.5M Series A Financing Led by MPM Capital and F2 Ventures -

December 2, 2016

Chris Bardon, MPM Managing Director, Comments to Bloomberg on New Approaches to Medical Philanthropy

Read full article – “A Few Billionaires Are Turning Medical Philanthropy on Its Head”

November 28, 2016

Epizyme Announces Fast Track Designation for Tazemetostat in DLBCL and Provides Tumor Program Update

November 21, 2016

Novartis Acquires MPM Portfolio Company Selexys Pharmaceuticals Corporation and SelG1 Antibody for Reduction of Pain Crises in Sickle Cell Disease

November 8, 2016

Harpoon Therapeutics Appoints Hans-Peter Gerber, PhD, As Chief Scientific Officer

November 7, 2016

Semma Therapeutics Announces Mark Fishman, M.D. Has Joined Its Board of Directors as Chairman

October 31, 2016

MPM Portfolio Company Epizyme Expands Clinical Programs through Cooperative Research and Development Agreements with the National Cancer Institute

October 27, 2016

Motus Therapeutics Inc., a Subsidiary of MPM Portfolio Company Rhythm Holding Co., LLC is to be Acquired by Allergan

Acquisition Announced Following Positive Results for Phase 2b Clinical Trial of Treatment for GI Disorders

October 13, 2016

True North Therapeutics Receives FDA Orphan Drug Designation for TNT009 for the Treatment of Autoimmune Hemolytic Anemia, Including Cold Agglutinin Disease (CAD)

October 11, 2016

Pacira Pharmaceuticals’ Kristen Williams is Honored as 1 of 15 “Fierce Women in Biopharma 2016”

Learn why Kristen stands out among women in the industry

September 22, 2016

iOmx Therapeutics Raises EUR 40 Million in Series A round

Company establishes top-tier investor base consisting of MPM Capital, Sofinnova Partners, Wellington Partners and Merck Ventures

September 19, 2016

Three MPM Portfolio Companies (Blade, Oncorus & Rhythm) Named to FierceBiotech’s “2016 Fierce 15” List

September 19, 2016

Radius Announces Publication of Additional Positive Results from the Phase 3 Active Trial of Osteoporosis Treatment

September 14, 2016

Tizona Therapeutics, Inc. Appoints George Golumbeski, Ph.D., to its Board of Directors

August 16, 2016

Osteoporosis, a Disease With Few Treatment Options, May Soon Have One More

Read coverage in NY Times and in Press Release

Aratana Secures Third FDA Approval

Animal pain drug expected to be available to veterinarians in the fall of 2016

August 11, 2016

Harvard Medical School Appoints MPM Medical and Scientific Advisory Co-Chair George Daley as New Dean

Read more in The Boston Globe

August 10, 2016

Iconic Therapeutics Announces Final Close of Series C Financing With Additional $10 Million Investment

August 1, 2016

Astellas and MPM Capital Launch DigiTx Partners

July 26, 2016

MPM Portfolio Company Blade Therapeutics Featured in the San Francisco Business Times

The July 19 article, “Taking it personally, cutting–edge biotech snags $45 million,” discusses the latest round of funding for Blade, a company focused on finding therapies for fibrotic disease, and MPM Co-Founder Luke Evnin’s personal commitment to the cause.

July 21, 2016

Rhythm Announces New England Journal of Medicine Publication of Setmelanotide Phase 2 Data for Treatment of POMC Deficiency Obesity

Significant weight loss with targeted treatment for patients with rare genetic defect in critical weight regulation pathway

July 20, 2016

Former Bluebird Bio (BLUE) CSO Takes the Reins at Oncorus; Startup Launches with $57 Million Series A

June 16, 2016

MPM Portfolio Company Semma Therapeutics Featured in Boston Globe

Boston-area hospitals have teamed up with the Harvard Stem Cell Institute and Semma Therapeutics to make personalized cell-based therapies and organize clinical trials.

June 2, 2016

Chris Bardon, Managing Director for the Oncology Impact Fund, on Bloomberg Capital Markets

Discussing Advances in Cancer Therapies as the 2016 ASCO Annual Meeting Gets Underway

May 27, 2016

TriNetX Enters into Collaboration with Celgene

Advance Clinical Trial Design and Research for Next-Generation Medicines Planned

May 18, 2016

Aratana Therapeutics Granted FDA Approval of ENTYCE®

First-of-its-Kind Ghrelin Mimetic

May 3, 2016

MPM Launches $471 Million Social Impact Oncology Fund

April 29, 2016

UBS Cancer Fund Shows Power of Impact Investing

A new oncology fund will finance academic research and access to cancer care in developing countries

April 28, 2016

UBS, MPM Seek Big ‘Impact’ in Cancer Drugs with $471M Fund

By Marie Powers, BioWorld Today, April 28, 2016

April 27, 2016

UBS Raises Record $471 Million for Oncology Impact Fund

BioSpace.com 4/27/2016

March 21, 2016

Aratana Therapeutics Granted First FDA Approval

Galliprant for the Control of Pain and Inflammation Associated with Osteoarthritis in Dogs

March 14, 2016

Chiasma Initiates Phase 3 Trial to Support European Registration of Octreotide Capsules for Patients with Acromegaly

March 8, 2016

Tizona Therapeutics, Inc., Completes $43 Million Series B Financing

March 6, 2016

Radius Health Submits New Drug Application to the U.S. Food and Drug Administration for Abaloparatide-SC for the Treatment of Postmenopausal Women with Osteoporosis

March 3, 2016

Nasdaq Welcomes Syndax Parmaceuticals, Inc. to The Nasdaq Stock Market

January 9, 2016

Iconic Therapeutics Closes Series C Financing

October 15, 2015

Semma Therapeutics named FierceMedicalDevices’ 2015 Fierce 15

August 27, 2015

Syndax Enters Clinical Trial Collaboration in Cancer Immunotherapy Combining Entinostat and Atezolizumab

August 24, 2015

Syndax Raises $80 Million in Series C Financing

August 17, 2015

Rhythm Subsidiary Raises $40 Million in Oversubscribed Financing

Financing to advance Rhythm Metabolic, Inc.'s setmelanotide program for rare genetic disorders of obesity

August 15, 2015

Epizyme Appoints Robert Bazemore President and Chief Executive Officer

July 16, 2015

Chiasma, Inc. Prices Initial Public Offering of Common Stock

July 10, 2015

Taking Clinical Trials Out of the Dark Ages (Clinical Ink)

June 23, 2015

Briggs W. Morrison, M.D., CEO of Syndax, Appointed Key Strategic Advisor to MPM Capital

June 15, 2015

Chiasma Submits New Drug Application to U.S. FDA for Octreotide Capsules in Acromegaly

Submission based on positive results from Phase 3 clinical trial

June 1, 2015

K. Peter Hirth, PhD, Joins Iconic Therapeutics as Board Member and Senior Scientific Advisor

May 21, 2015

MPM Capital appoints Pablo J. Cagnoni, M.D., former Onyx Pharmaceuticals President, as Managing Director and CEO of MPM immunotherapy portfolio company Vesuvius

May 14, 2015

MPM closes $400 million fund

May 5, 2015

23andMe Launches the Lupus Research Study in Collaboration with Pfizer Inc.

With Lupus Awareness Month Underway, Study Aims to Build a 5,000-Patient Lupus Cohort to Advance Understanding of the Disease

April 22, 2015

Astellas Pharma and Potenza Therapeutics Partner to Build a Portfolio of Immuno-oncology Therapeutics

Exclusive Collaboration Includes Option for Astellas to Acquire Potenza

April 15, 2015

Novartis International Global Head M&A and Licensing Anthony Rosenberg to join as Managing Director, effective April 1, 2015

- To serve as strategic advisor and on MPM portfolio boards to build leading companies -

March 24, 2015

Biotech Startup to Fight Diabetes on the Cellular Front

Semma Therapeutics seeks to turn success in stem research lab into a way to encourage insulin production

March 24, 2015

Semma Therapeutics Announces $44 Million in Funding Led by MPM Capital to Develop Cell Therapy for Treating Type 1 Diabetes; Signs Agreement with Global Pharmaceutical Company

March 16, 2015

Ebb & Flow: Chiasma’s Private Decision

March 16, 2015

Chiasma Announces Mark Leuchtenberger as Chief Executive Officer

Proven Business Leader to Oversee Commercialization of Octreotide Capsules

March 12, 2015

23andMe to Create Therapeutics Group, Appoints Scientific Luminary, R&D Executive Richard Scheller, Ph.D. to Lead

Dr. Scheller Joins 23andMe’s Executive Leadership Team as Chief Science Officer and Head of Therapeutics

March 11, 2015

MPM Capital Announces Immuno-Oncology Pioneer Patrick Baeuerle to serve as Managing Director

-Top scientist and drug developer joins MPM senior team advancing breakthroughs and discoveries

March 10, 2015

Radius (RDUS) Announced Today That It Has Acquired The License To Develop And Market RAD1901 In Japan

Dinesh Purandare Hired (Former Sanofi (SAN.PA) Oncology Executive To The Position Of Senior Vice President (SVP) And Head Of Global Oncology At Radius )

February 27, 2015

Chiasma Announces Completion of $70 Million Series E Financing

February 27, 2015

Verastem Receives Orphan Drug Designation From FDA For VS-5584 In Mesothelioma

February 24, 2015

Chiasma Appoints David Stack as Chairman of the Board; John A. Scarlett, M.D. Joins Board of Directors

February 20, 2015

Syndax Says Immuno-oncology Discovery Happened Instead of an IPO

February 10, 2015

Chiasma Inc. Releases Newly Published Phase 3 Study Results

Show Positive Outcomes For Octreotide Capsules In People With Acromegaly, A Serious Hormonal Disorder

February 9, 2015

Radius, Celladon and Nevro Among Top IPOs in 2014

MPM has #1, 8 and 10 out of the top 14

January 1, 2015

Radius: The Top Performing IPO of 2014

Radius, which is developing treatments for osteoporosis, is up 364% since pricing its June 6 initial public offering at 8

December 22, 2014

Radius Announces Positive Phase 3 Top-Line Results

December 15, 2014

For Venture Capital, Biotech is Where It’s Really At

August 4, 2014

Aratana Featured: Start-Ups Work on Biotech Drugs for Pets

June 17, 2014

True North snags $22M and sets course for the clinic with a rare disease drug

April 29, 2014

iPierian acquired by Bristol-Myers Squibb

Advances discovery strategy to pursue therapeutics for genetically defined diseases

April 16, 2014

Iconic Therapeutics Raises $20 Million to Advance Clinical Development of Wet AMD Program

William Greene, MD, Appointed Chief Executive Officer

April 14, 2014

Celladon Receives Breakthrough Therapy Designation from FDA

MYDICAR is First Gene Therapy Reported to Receive Breakthrough Designation from FDA’s Center for Biologics Evaluation and Research (CBER)

February 18, 2014

CoStim Pharmaceuticals, Inc. Acquired by Novartis

January 27, 2014

MPM Capital and Kleiner Perkins Caufield & Byers top the list of investors with the most 2013 IPOs

January 7, 2014

Epizyme and Celgene Advance EPZ-5676 DOT1L Inhibitor Clinical Program to Benefit Cancer Patients with Acute Leukemias, Achieving $25 Million Clinical Proof of Concept Milestone